Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05506800 Suspended - Breast Cancer Clinical Trials

Guangzhou Women's Health Cohort Study (GWHCS)

Start date: March 3, 2016
Phase:
Study type: Observational

The Guangzhou Women's Health Cohort Study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in Guangzhou. Based on multiple population health registration data platforms, data of the cohort will provide information about the health of women across the lifespan, facilitating the decision-making process by local government . The cohort is progressing steadily, and the goal is to build a large women cohort covering 11 administrative districts of Guangzhou with a scale of 1 million by 2030.

NCT ID: NCT05374603 Suspended - Lung Cancer Clinical Trials

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

SOUND
Start date: November 23, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, interventional, multiple-center, exploratory Phase II study sponsored by AstraZeneca Investment(China)Co., LTD. to evaluate the efficacy and safety of Savolitinib combine with Durvalumab in Chinese EGFR wild-type locally advanced or metastatic NSCLC patients with MET alteration.

NCT ID: NCT04115254 Suspended - Prostate Cancer Clinical Trials

Stereotactic Magnetic Resonance Guided Radiation Therapy

Start date: October 22, 2019
Phase: N/A
Study type: Interventional

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. - The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. - Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

NCT ID: NCT02579005 Suspended - Lung Cancer Clinical Trials

Radio-Immuno-Modulation in Lung Cancer

RIM
Start date: April 20, 2018
Phase: Phase 1
Study type: Interventional

This project will assess the feasibility of treating advanced cancer using the immune system, without any anti-cancer drug. In this pilot study, the investigators propose combining low-dose radiotherapy, in lung cancer patients, with allogeneic immune cells obtained from a donor. The patients will receive radiotherapy directed to one of the patient's tumors, as well as an immunomodulatory drug called cyclophosphamide. Thereafter, they will receive the infusion of donor immune cells.